

# ARD

Annals of the Rheumatic Diseases  
The EULAR Journal

## Editor

Leo van de Putte (The Netherlands)

## Associate editors

Thomas Bardin (France)  
Johannes Bijlsma (The Netherlands)  
Gerd Burmester (Germany)

Bevrah Hahn (USA)  
Frank Wollheim (Sweden)  
Anthony Woolf (UK)

## Methodological adviser

Jaap Fransen (The Netherlands)

## Editorial board

M Aringer (Austria)  
P Bacon (UK)  
F Berenbaum (France)  
M Boers (The Netherlands)  
D Boumpas (Greece)  
B Bresnihan (Ireland)  
H Capell (UK)  
M Cutolo (Italy)  
G Firestein (USA)  
P Goupille (France)  
E Gravallese (USA)  
W Gross (Germany)  
F Guillemain (France)  
G Herrero-Beaumont (Spain)  
F Houssiau (Belgium)  
T Huizinga (The Netherlands)  
C Jorgensen (France)  
G Kollias (Greece)  
T Kvien (Norway)  
M Leirisalo-Repo (Finland)  
F Luijten (Belgium)  
H-M Lorenz (Germany)  
W Maslinski (Poland)  
M Matucci Cerinic (Italy)

K Nishioka (Japan)  
M Nurmohamed  
(The Netherlands)  
S Özen (Turkey)  
T Pap (Germany)  
E Pascual Gómez (Spain)  
L Punzi (Italy)  
L Rönnblom (Sweden)  
B Rozman (Slovenia)  
G Schett (Austria)  
J Da Silva (Portugal)  
H Schulze-Koops (Germany)  
A So (Switzerland)  
T Sokka (USA)  
D Symmons (UK)  
P-P Tak (The Netherlands)  
A Tyndall (Switzerland)  
A Tzioufas (Greece)  
J Vencovsky (Czech Republic)  
M Ward (USA)  
M Weisman (USA)  
H Yazici (Turkey)  
Editor, *BMJ*

## Advisory committee

W vd Berg (The Netherlands)  
S Bombardieri (Italy)  
F Breedveld (The Netherlands)  
L Crofford (USA)  
J-M Dayer (Switzerland)  
M Doherty (UK)  
M Dougados (France)  
J Edmonds (Australia)  
P Emery (UK)  
D Furst (USA)  
S Gay (Switzerland)  
J Kalden (Germany)  
E Keystone (Canada)  
L Klarenskog (Sweden)

P Lipsky (USA)  
S Lohmander (Finland)  
R Maini (UK)  
E M Mola (Spain)  
H Moutsopoulos (Greece)  
J O'Dell (USA)  
K Pavelka (Czech Republic)  
J Rovinsky (Slovakia)  
Y Shoenfeld (Israel)  
J Smolen (Austria)  
W van Venrooy  
(The Netherlands)  
E Veys (Belgium)  
A Wiik (Denmark)

## Guidelines for authors and reviewers

Guidance for authors and reviewers can be found at <http://ard.bmj.com/fora>  
All papers must be submitted via Bench>Press at [www.submit-ard.bmj.com](http://www.submit-ard.bmj.com)

## Disclaimer

*Annals of the Rheumatic Diseases* is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

## Subscription information

See p iv  
ISSN 0003-4967 (print); 1468-2060 (online)


## Copyright

© 2007 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/fora/licence.dtl>

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, copyedited by Macmillan India Ltd, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth

• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Joints with rheumatoid arthritis and spondylarthropathis.  
See p709

## contents ARD

Volume 66 Number 6 June 2007

## Editorial

- 709 Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? *G Schett, R Landewé, D van der Heijde*

## Extended reports

- 712 Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines *W Hueber, B H Tomooka, X Zhao, B A Kidd, J W Drijfhout, J F Fries, W J van Venrooij, A L Metzger, M C Genovese, W H Robinson*

- 720 Ectopic lymphoid neogenesis in psoriatic arthritis *J D Cañete, B Santiago, T Cantaert, R Sanmartí, A Palacin, R Celis, E Graell, B Gil-Torregrosa, D Baeten, J L Pablos*

- 727 Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis *S M M Verstappen, J W G Jacobs, D M van der Heijde, S J van der Linden, C M Verhoef, J W J Bijlsma, A Boonen*

- 732 Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial *G R Burmester, X Mariette, C Montecucco, I Monteagudo-Sáez, M Malaise, A G Tzioufas, J W J Bijlsma, K Unnebrink, S Kary, H Kupper, on behalf of the Research in Active Rheumatoid Arthritis Trial study group*

- 740 Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases *J A Gómez-Puerta, R Cervera, G Espinosa, R A Asherson, M García-Carrasco, I P da Costa, D C O Andrade, E F Borba, A Makatsaria, S Bucciarelli, M Ramos-Casals, J Font, for the Catastrophic Antiphospholipid Syndrome Registry Project Group/European Forum on Antiphospholipid Antibodies*

- 747 Superiority of the Lyon schuss view over the standing anteroposterior view for detecting joint space narrowing, especially in the lateral tibiofemoral compartment, in early knee osteoarthritis *F Merle-Vincent, E Vignon, K Brandt, M Piperno, F Coury-Lucas, T Conrozier, P Mathieu, M P Hellio Le Graverand*

- 754 Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database *U A Walker, A Tyndall, L Czirják, C Denton, D Farge-Bancel, O Kowal-Bielecka, U Müller-Ladner, C Bocelli-Tyndall, M Matucci-Cericin, EUSTAR Co-authors\**

- 764 Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib *M E Farkouh, J D Greenberg, R V Jeger, K Ramanathan, F W A Verheugt, J H Chesebro, H Kirshner, J S Hochman, C L Lay, S Ruland, B Mellein, P T Matchaba, V Fuster, S B Abramson*



[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

- 771 How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? *A Boonen, D van der Heijde, R Landewé, A van Tubergen, H Mielants, M Dougados, S van der Linden*
- 778 Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis *H Marzo-Ortega, D McGonagle, L A Rhodes, A Lyn Tan, P G Conaghan, P O' Connor, S F Tanner, A Fraser, D Veale, P Emery*
- 782 Inhibition of interleukin 1-induced matrix metalloproteinase 13 expression in human chondrocytes by interferon  $\gamma$  *R Ahmad, H Y Qureshi, M El Mabrouk, J Sylvester, M Ahmad, M Zafarullah*
- 790 Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus *J Sellam, C Miceli-Richard, J-E Gottenberg, M Ittah, F Lavie, C Lacabaratz, N Gestermann, A Proust, O Lambotte, X Mariette*
- 798 Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide *P M Stassen, J W Cohen Tervaert, C A Stegeman*
- 803 FCRL3 promoter 169 CC homozygosity is associated with susceptibility to rheumatoid arthritis in Dutch Caucasians *M M Thabet, J Wesoly, P E Slagboom, R E M Toes, T W J Huizinga*
- 807 HLA-Cw6 and HLA-DRB1\*07 together are associated with less severe joint disease in psoriatic arthritis *P Y P C Ho, A Barton, J Worthington, W Thomson, A J Silman, I N Bruce*
- .....
- Concise reports**
- 812 Reversal of Sjögren's-like syndrome in non-obese diabetic mice *S D Tran, S Kodama, B M Lodde, I Szalayova, S Key, S Khalili, D L Faustman, É Mezey*
- 815 Antimalarials may influence the risk of malignancy in systemic lupus erythematosus *G Ruiz-Irastorza, A Ugarte, M V Egurbide, M Garmendia, J I Pijoan, A Martinez-Berrioxoa, C Aguirre*
- 818 Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis *E Toubi, A Kessel, G Slobodin, N Boulman, E Pavlotzky, D Zisman, M Rozenbaum, I Rosner*
- 821 Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus *N Costedoat-Chalumeau, Z Amoura, J-S Hulot, G Aymard, G Leroux, D Marra, P Lechat, J-C Piette*
- 825 Ultrasonographic measurement of the median nerve in patients with rheumatoid arthritis without symptoms or signs of carpal tunnel syndrome *H Berner Hammer, E A Haavardsholm, T K Kvien*
- 828 IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis *S Garnier, P Dieudé, L Michou, S Barbet, A Tan, S Lasbleiz, T Bardin, B Prum, F Cornélis, for ECRAF<sup>†</sup>*
- 832 Autoinflammatory gene mutations in Behçet's disease *I Koné-Paut, E Sanchez, A Le Quellec, R Manna, I Touitou*
- .....
- Letters**
- 835 Rheumatoid arthritis in Dubai—delayed diagnosis and low usage of disease modifying antirheumatic drugs *H Badsha, K O Kong, P P Tak*
- 836 Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? *J H W Distler, O Distler*
- 837 Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis *J Pradeep, R Watts, G Clunie*
- 838 N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis? *T Häupl, G R Burmester, E Giannitsis, T Rohrlach, E Spanuth, H Parsch, K Brune*
- 840 Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease *S M Sharma, A V Ramanan, P Riley, A D Dick*
- 842 Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial *G D Kalliolias, P E Georgiou, I A Antonopoulos, A P Andonopoulos, S-N C Liossis*
- 843 Cryopyrin-associated autoinflammatory syndrome: a new mutation *A Zeff, J F Bohnsack*
- 844 DNA microarray analysis of labial salivary glands of patients with Sjögren's syndrome *E Wakamatsu, Y Nakamura, I Matsumoto, D Goto, S Ito, A Tsutsumi, T Sumida*
- 846 Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations *M Y Mok, E Y T Chan, W S Wong, C S Lau*
- 847 Forthcoming events  
Correction